95 related articles for article (PubMed ID: 26424521)
1. The double-edged sword of neutrophilic inflammation in bronchiectasis.
Martínez-García MÁ; Sánchez CP; Moreno RM
Eur Respir J; 2015 Oct; 46(4):898-900. PubMed ID: 26424521
[No Abstract] [Full Text] [Related]
2. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils.
Pedersen F; Waschki B; Marwitz S; Goldmann T; Kirsten A; Malmgren A; Rabe KF; Uddin M; Watz H
Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29449427
[No Abstract] [Full Text] [Related]
4. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
Leaker BR; Barnes PJ; O'Connor B
Respir Res; 2013 Dec; 14(1):137. PubMed ID: 24341382
[TBL] [Abstract][Full Text] [Related]
5. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
[TBL] [Abstract][Full Text] [Related]
6. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma.
Watz H; Uddin M; Pedersen F; Kirsten A; Goldmann T; Stellmacher F; Groth E; Larsson B; Böttcher G; Malmgren A; Kraan M; Rabe KF
Pulm Pharmacol Ther; 2017 Aug; 45():121-123. PubMed ID: 28549850
[No Abstract] [Full Text] [Related]
7. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
Nicholls DJ; Wiley K; Dainty I; MacIntosh F; Phillips C; Gaw A; Mårdh CK
J Pharmacol Exp Ther; 2015 May; 353(2):340-50. PubMed ID: 25736418
[TBL] [Abstract][Full Text] [Related]
8. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis.
Tsang KW; Ho PL; Lam WK; Ip MS; Chan KN; Ho CS; Ooi CC; Yuen KY
Am J Respir Crit Care Med; 1998 Sep; 158(3):723-7. PubMed ID: 9730996
[TBL] [Abstract][Full Text] [Related]
9. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis.
Guran T; Ersu R; Karadag B; Karakoc F; Demirel GY; Hekim N; Dagli E
J Clin Pharm Ther; 2008 Dec; 33(6):603-11. PubMed ID: 19138237
[TBL] [Abstract][Full Text] [Related]
10. The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates.
Uddin M; Betts C; Robinson I; Malmgren A; Humfrey C
Haematologica; 2017 Feb; 102(2):e65-e68. PubMed ID: 27742769
[No Abstract] [Full Text] [Related]
11. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion.
Llewellyn-Jones CG; Johnson MM; Mitchell JL; Pye A; Okafor VC; Hill SL; Stockley RA
Eur Respir J; 1995 Sep; 8(9):1479-87. PubMed ID: 8575572
[TBL] [Abstract][Full Text] [Related]
12. Neutrophils in chronic inflammatory airway diseases: can we target them and how?
Gernez Y; Tirouvanziam R; Chanez P
Eur Respir J; 2010 Mar; 35(3):467-9. PubMed ID: 20190324
[No Abstract] [Full Text] [Related]
13. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis.
Lin HC; Cheng HF; Wang CH; Liu CY; Yu CT; Kuo HP
Am J Respir Crit Care Med; 1997 Jun; 155(6):2024-9. PubMed ID: 9196111
[TBL] [Abstract][Full Text] [Related]
14. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.
Moss RB; Mistry SJ; Konstan MW; Pilewski JM; Kerem E; Tal-Singer R; Lazaar AL;
J Cyst Fibros; 2013 May; 12(3):241-8. PubMed ID: 22995323
[TBL] [Abstract][Full Text] [Related]
15. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
Aul R; Patel S; Summerhill S; Kilty I; Plumb J; Singh D
Int Immunopharmacol; 2012 Jul; 13(3):225-31. PubMed ID: 22561413
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.
Stockley R; De Soyza A; Gunawardena K; Perrett J; Forsman-Semb K; Entwistle N; Snell N
Respir Med; 2013 Apr; 107(4):524-33. PubMed ID: 23433769
[TBL] [Abstract][Full Text] [Related]
17. Effect of H1- and H2-receptor antagonists on sputum volume and lung function in patients with generalized bronchiectasis.
Anderson J; Eiser NM; Mills JG
Br J Dis Chest; 1985 Jul; 79(3):272-4. PubMed ID: 2861844
[TBL] [Abstract][Full Text] [Related]
18. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis.
Tsikrika S; Dimakou K; Papaioannou AI; Hillas G; Thanos L; Kostikas K; Loukides S; Papiris S; Koulouris N; Bakakos P
Cytokine; 2017 Nov; 99():281-286. PubMed ID: 28863927
[TBL] [Abstract][Full Text] [Related]
19. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
[TBL] [Abstract][Full Text] [Related]
20. Role of bromhexine in exacerbations of bronchiectasis. Double-blind randomized multicenter study versus placebo.
Olivieri D; Ciaccia A; Marangio E; Marsico S; Todisco T; Del Vita M
Respiration; 1991; 58(3-4):117-21. PubMed ID: 1745841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
